Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27172785 | 0.90 | TSHR (0.45) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL29191646 | 0.89 | TSHR (0.43) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL3323881 | 0.86 | KMT2A (0.49) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL12872517 | 0.83 | TSHR (0.50) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL19251123 | 0.83 | AGXT (0.44) | CA1CA2CA9TACR1HTT | |
| SCHEMBL11045891 | 0.82 | CA1 (0.58) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL1105211 | 0.81 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9715485 | 0.81 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL18658511 | 0.81 | TSHR (0.48) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL27942179 | 0.81 | CA1 (0.57) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023033605-A1 | METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| WO-2023033601-A1 | METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| US-5623081-A | USING BENZYLOXYACETALDEHYDE DIMETHYL ETHER, HALOGENATED 1-PHENYLMETHOXY-4-PENTEN-2-OL; CYCLIZATION | LIN YANG-I (US) | 1997-04-22 | — | — | US | claimed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-27 | — | — | US | disclosed |
| EP-4612145-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-09-10 | — | — | EP | disclosed |
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | disclosed |
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-0332025-B1 | CHIRAL DERIVATIVES OF 1,2-DIFLUOROBENZENES | MERCK PATENT GmbH (DE) | 1993-06-23 | — | — | EP | disclosed |
| EP-0428665-A1 | FLUOROPHENYL PYRIMIDINES. | MERCK PATENT GMBH (DE) | 1991-05-29 | — | — | EP | disclosed |
| EP-0428720-A1 | OPTICALLY ACTIVE COMPOUNDS AND LIQUID CRYSTAL PHASE. | MERCK PATENT GMBH (DE) | 1991-05-29 | — | — | EP | disclosed |
| WO-1990015116-A1 | FLUOROPHENYL PYRIMIDINES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-12-13 | — | — | WO | disclosed |
| WO-1990013611-A2 | OPTICALLY ACTIVE COMPOUNDS AND LIQUID CRYSTAL PHASE | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-11-15 | — | — | WO | disclosed |
| EP-0357739-A1 | CHIRAL DERIVATIVES OF 1,2-DIFLUOROBENZENE | MERCK PATENT GmbH (DE) | 1990-03-14 | — | — | EP | disclosed |
| WO-1989008639-A1 | CHIRAL DERIVATIVES OF 1,2-DIFLUOROBENZENE | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332025-A1 | Chiral derivatives of 1,2-difluorobenzenes | MERCK PATENT GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
| US-4077982-A | HERBICIDES | FMC CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | TSHR 309/4885CA1 1166/4885CA2 662/4885 |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | TSHR 309/4885CA1 1166/4885CA2 662/4885 |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | HCRTR2, HCRTR1, NPY1R | TSHR 88/4885CA1 304/4885CA2 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.